2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Precipio reported second-quarter 2026 revenue of $7.0 million, up from $6.7 million in the first quarter and 22% above the $5.7 million in the year-earlier quarter. Adjusted EBITDA, a non-GAAP measure, was $0.4 million, compared with a $(0.2) million loss in the first quarter, but the company's GAAP net result was a loss of $(0.2) million versus net income of $0.1 million a year earlier.
Q2 2026 revenue was $7.0 million, including $6.1 million in pathology revenue and $0.9 million in product revenue.
Adjusted EBITDA was $0.4 million in Q2 2026, versus $(0.2) million in Q1 2026.
GAAP net loss was $(0.2) million in Q2 2026, compared with net income of $0.1 million in Q2 2025.
Cash was over $3 million at quarter end, versus $1.1 million in Q2 2025, with $0.7 million generated from operations in the quarter.
MediaCo reported second-quarter 2026 net revenues of $34.0 million, up 9% from a year earlier, driven by digital advertising. Net loss widened 17% to $8.6 million, and Adjusted EBITDA fell 38% to $0.9 million, so higher revenue did not translate into better profitability for shareholders.
Q2 2026 net revenues were $34.0 million ($33,969 thousand), up 9% from $31.2 million in Q2 2025.
Q2 2026 net loss was $8.6 million, compared with $7.4 million a year earlier, citing higher operating and corporate expenses and interest costs.
Q2 2026 Adjusted EBITDA was $0.9 million, down from $1.5 million in Q2 2025.
First-half 2026 net revenues were $65.4 million, up 10%, while the first-half net loss was $18.0 million versus $16.0 million.
Canton Strategic Holdings reported its first operating revenue for the quarter ended June 30, 2026, $1,495,859, compared with $0 a year earlier. The company also posted a net loss of $19,254,826, or $(0.08) per share, which includes a $23,735,950 unrealized loss on its Canton Coin holdings, so the larger loss and the revenue gain both bear on shareholder returns.
Total revenue was $1,495,859 for the three months ended June 30, 2026, versus $0 in the same period of 2025; the filing says the LaaS offering drove about $1.3 million of it.
Net loss was $19,254,826, or $(0.08) per basic and diluted share from continuing operations, including a $23,735,950 unrealized loss on digital asset holdings.
Cash and cash equivalents were $37,241,568 as of June 30, 2026, up from $12,007,148 as of December 31, 2025.
The sale of Gravitas Life Sciences, Inc. closed on July 17, 2026, for an unsecured promissory note of $3,500,000 bearing 15% payment-in-kind interest, plus contingent milestone payments.
KinderCare Education, a wholly-owned subsidiary, entered into an Amended and Restated Fifth Amendment to its master lease covering 545 center sites with landlord KCP RE LLC, effective August 11, 2026. The amendment extends lease terms to between December 31, 2033 and December 31, 2042 for most sites, but raises the cap on annual rent escalations from 10% to 12.5%, which increases the potential cost of future rent adjustments.
Schedule 1 (13 sites) was transferred to affiliate KCP RE II LLC under a new master lease ending December 31, 2029, at the same annual rent.
Lease expirations for Schedules 2 through 6 range from December 31, 2033 to December 31, 2042, with one five-year extension option for Schedules 4 through 6.
The escalation percentage is the lesser of 12.5% (previously 10%) or the applicable index increase, with adjustment dates from August 1, 2030.
Air T reported fiscal 2027 first-quarter results for the period ended June 30, 2026, with revenue up 63% to $115.5 million but an operating loss of $12.8 million compared with operating income of $0.8 million a year earlier. The company attributed the loss mainly to transaction and integration costs for Crestone's June 10 acquisition of Arena Aviation Capital and to depreciation from the fair-value step-up of the Rex aircraft fleet. Shareholders are seeing higher revenue alongside lower profitability in the quarter.
Q1 revenue was $115.5 million, up $44.6 million, or 63%, from the prior-year quarter.
Q1 operating loss was $12.8 million versus operating income of $0.8 million a year earlier; Adjusted EBITDA was $0.8 million, down 45% from $1.5 million.
Trailing twelve-month revenue was $371.7 million, up 25%, while the trailing twelve-month operating loss was $24.9 million.
Crestone acquired Arena Aviation Capital on June 10 for $33.9 million, including $21.7 million in cash and $12.2 million of contingent consideration; Blue Owl funded $10.0 million for preferred units representing 10.25% of the platform.
Air T reported fiscal first-quarter 2027 revenue of $115.5 million, up 63% from a year earlier, with $55.9 million coming from its Rex regional airline acquisition completed on December 18, 2025. The company swung to an operating loss of $12.8 million from operating income of $0.8 million a year earlier, and net loss per share was $5.86 versus $0.61, so higher sales did not translate into profit for shareholders.
Revenue $115.5 million, up $44.6 million or 63%; Rex contributed $55.9 million
Operating loss $12.8 million versus operating income of $0.8 million in the prior-year quarter
Net loss per share $5.86 versus $0.61; loss before income taxes $15.0 million versus $0.8 million
Adjusted EBITDA (a non-GAAP measure) $0.8 million versus $1.5 million; Regional Airline segment cited fuel expense of $11.8 million as the primary driver of its operating loss
Maui Land & Pineapple reported results for the six months ended June 30, 2026, in Exhibit 99.1 to a Form 8-K. Total operating revenues fell to $7.1 million from $10.4 million a year earlier, while the net loss narrowed to $3.7 million from $9.6 million, mainly because the prior year included pension charges. Shareholders face lower revenue and a higher line of credit balance alongside the smaller loss.
Total operating revenues were $7.1 million for the six months ended June 30, 2026, versus $10.4 million a year earlier.
Net loss was $3.7 million, or $0.19 per share, versus $9.6 million, or $0.49 per share, a year earlier.
Land development and sales revenue was $0.5 million, down from $4.1 million; the company cited contracted sales, including a $10.0 million agreement with Harvest Church expected to close in 2027.
Cash and cash equivalents were $3.3 million at June 30, 2026, and the line of credit balance rose to $8.5 million from $4.0 million at December 31, 2025.
AgEagle reported second quarter 2026 revenue of $2.7 million, nearly double the first quarter but down from $4.1 million in the second quarter of 2025. Cash and cash equivalents fell to $15.9 million at June 30, 2026, from $29.5 million at December 31, 2025, so the sequential rebound comes with lower year-over-year sales and a smaller cash balance.
Revenue of $2.7 million, compared with $1.4 million in Q1 2026 and $4.1 million in Q2 2025
Gross margin of 50.6%, up from 41.7% in Q1 2026 but below 56% in Q2 2025
Cash and cash equivalents of $15.9 million at June 30, 2026, down from $29.5 million at December 31, 2025
Company expects continued revenue progression in the second half of 2026 but gave no numeric guidance; nine eBee VISION systems are expected to ship in Q3 2026
Solana Company reported a second-quarter 2026 net loss of $30.3 million, or $0.38 per share, compared with a net loss of $9.8 million in the prior-year quarter. Revenue rose to $2.5 million, mainly from staking on its SOL holdings, but operating expenses reached $35.1 million, including $6.8 million of severance tied to the divestiture of its legacy PoNS medical device business.
Q2 2026 revenue was $2.5 million, almost all staking revenue, versus $43 thousand a year earlier
Q2 2026 net loss was $30.3 million, or $0.38 per share, versus $9.8 million in the prior-year quarter
General and administrative expenses were $11.1 million, including $6.8 million of severance tied to the PoNS divestiture
Total assets were $176.1 million at June 30, 2026, down from $303.9 million at December 31, 2025, and cash was $3.6 million
Seritage Growth Properties reported second-quarter 2026 results with a net loss attributable to common shareholders of $7.4 million, or $0.13 per share, compared with $29.7 million, or $0.53 per share, a year earlier. Revenue fell sharply to $1.9 million from $4.7 million, while the company repaid its $50.0 million term loan using new loans and cash on hand, and said it continues to explore a strategic transaction.
Q2 2026 net loss attributable to common shareholders was $7.4 million ($0.13 per share), versus $29.7 million ($0.53 per share) in Q2 2025.
Q2 2026 total revenue was $1.9 million, versus $4.7 million in Q2 2025.
Six-month net loss was $38.9 million ($0.69 per share), including a $15.2 million impairment on one consolidated property.
On July 24, 2026, the company closed a $15.0 million term loan and $25.0 million revolver, drew $15.0 million, and repaid the $50.0 million term loan balance.
Gaxos.ai agreed with holders of existing warrants to exercise 3,007,654 shares at a reduced price of $1.20 per share, down from original exercise prices of $2.33 to $3.32. In exchange, the company will issue new warrants for up to 6,015,308 shares at $0.95 per share, with a three-year term. Gross proceeds are expected to be about $3.6 million before placement agent fees and offering expenses, which would add cash for working capital but could increase the number of shares outstanding if the new warrants are exercised.
Existing warrants for 3,007,654 shares to be exercised at $1.20 per share, with gross proceeds of about $3.6 million expected before fees
New warrants for up to 6,015,308 shares at $0.95 per share, with a three-year term
H.C. Wainwright & Co. is placement agent, with a 7.0% cash fee and 1.0% management fee on exercise proceeds, plus warrants for 150,383 shares at $1.50
Closing expected on August 17, 2026; company to file a resale registration statement within 30 days of closing
Barfresh reported second quarter 2026 revenue of $4.7 million, up 190% year over year, driven by the Arp's Dairy acquisition. The company also reported a gross loss, a net loss of $1.9 million and an Adjusted EBITDA loss of $1.2 million, and it revised its full year 2026 guidance lower, citing slower production efficiency gains at its existing facility.
Q2 2026 revenue was $4.7 million, up from $1.6 million in Q2 2025, with a gross loss of $150,000 versus gross profit of $506,000 a year earlier.
Q2 2026 net loss was $1.9 million, compared with $880,000 in Q2 2025; Adjusted EBITDA loss was $1.2 million, compared with $600,000.
FY 2026 revenue guidance is $23 million to $26 million, or 62% to 83% growth; FY 2026 Adjusted EBITDA guidance is negative $1.0 million to $2.0 million.
The company expects Adjusted EBITDA of negative $0.5 million to breakeven in the second half of 2026.
Femasys reported that quarterly sales fell 18.9% to $331,827 in the quarter ended June 30, 2026, mainly due to lower FemVue sales, while the quarterly net loss narrowed slightly to $4.47 million from $4.59 million. The company had about $1.4 million of cash at June 30, 2026, and completed a $30 million private placement after quarter-end, which it says gives it resources for its commercial and clinical plans and restored Nasdaq listing compliance.
Quarterly sales were $331,827, down $77,441 or 18.9% from $409,268 a year earlier; six-month sales rose 0.8% to $756,716.
Quarterly net loss was $4,469,095, or $(1.33) per share, versus $4,585,922, or $(3.18) per share, a year earlier; six-month net loss was $3,622,995 versus $10,482,761.
Cash and cash equivalents were about $1.4 million at June 30, 2026, with a $30 million private placement completed after the quarter, which could bring up to $90 million if warrants are fully exercised.
The company said it regained compliance with Nasdaq Listing Requirements and appointed John Canning as Chief Operating Officer.
Motorsport Games reported second-quarter 2026 revenue of $3.5 million, up 36.6% from a year earlier, and first-half revenue of $7.6 million, up 74.0%. Net income fell to about $0.2 million from $4.2 million, and diluted EPS was $0.08 versus $0.82, because the prior-year quarter included non-recurring gains and development spending nearly tripled.
Q2 2026 revenue was $3.5 million versus $2.6 million in Q2 2025, an increase of 36.6%; six-month revenue was $7.6 million, up 74.0%.
Q2 2026 net income was about $0.2 million versus $4.2 million in Q2 2025; the prior year included $2.3 million in foreign exchange gains and a $0.8 million Wesco Settlement Agreement gain.
Non-GAAP Adjusted diluted EPS was $0.19 in Q2 2026 versus $0.25 a year earlier, and $0.33 for the six months versus $0.24; Q2 Adjusted EBITDA was $0.8 million versus $1.4 million.
Cash and cash equivalents were about $3.9 million at June 30, 2026, and $1.2 million was drawn on a $3 million Citibank revolving line of credit.
Ambow Education Holding reported unaudited results for the six months and three months ended June 30, 2026. First-half net revenues rose 2.0% to $5.2 million, but second-quarter revenue fell 14.3% and the company posted a net loss of $0.1 million, compared with net income of $1.8 million a year earlier, which included a one-time $1.5 million lease settlement gain.
Q2 2026 net revenues fell 14.3% to $2.4 million from $2.8 million, mainly due to lower HybriU licensing and sales.
Q2 2026 gross margin was 50.0%, compared with 53.6% a year earlier, and operating expenses rose 27.3% to $1.4 million.
First-half 2026 net income was $0.3 million, or $0.10 per ADS, versus $1.9 million, or $0.66 per ADS, in the first half of 2025.
Cash resources were $7.2 million as of June 30, 2026, and working capital was positive at $5.5 million.
Data Storage Corp reported second-quarter 2026 sales of $358,530, up from $327,951 a year earlier, while its net loss attributable to common stockholders widened to $1,225,515 from $733,049. The company completed a tender offer that cut its share count and said it is evaluating acquisitions of recurring-revenue technology businesses, with about $9.3 million in cash and marketable securities and no long-term debt.
Q2 2026 sales rose to $358,530 from $327,951; loss from operations widened to $1,282,070 from $950,762.
Loss per share attributable to common stockholders was $(0.55) for the quarter versus $(0.10) a year earlier.
Six-month share repurchases in connection with the tender offer totaled $29,528,957; treasury stock stood at 5,625,129 shares at June 30, 2026.
Cash and cash equivalents plus marketable securities were about $9.3 million at June 30, 2026, with no long-term debt, according to management.
Cue Biopharma reported a second quarter 2026 revenue increase to $7.9 million from $3.0 million, but its net loss grew to $153.1 million from $8.5 million. The company attributed the larger loss mainly to one-time non-cash losses and expenses tied to its CUE-221 license agreement with Ascendant, and it had $17.4 million in cash at June 30, 2026 before a $50 million private placement completed after quarter end.
Second quarter revenue was $7.9 million, versus $3.0 million a year earlier, driven by a preclinical milestone under the Boehringer Ingelheim collaboration.
Net loss was $153.1 million, or $24.14 per share, versus $8.5 million, or $2.67 per share, in the second quarter of 2025.
Cash and cash equivalents were $17.4 million at June 30, 2026; a $50 million private placement was completed after quarter end.
Phase 2 data readout for CUE-221 in Chronic Spontaneous Urticaria is anticipated by the end of the third quarter of 2026.
Dyadic International agreed on August 13, 2026 to sell 3,625,000 common shares at $0.795 each in a registered direct offering, plus warrants for another 3,625,000 shares in a concurrent private placement, for expected gross proceeds of about $2.9 million. The sale adds cash but also issues new shares and warrants that can dilute existing shareholders, and the company has agreed to a 90-day restriction on further share issuances.
3,625,000 common shares sold at $0.795 per share in a registered direct offering
Common warrants for 3,625,000 shares sold at $0.005 each, exercisable at $0.84 per share
Expected gross proceeds of about $2.9 million before offering expenses, closing on or about August 14, 2026
Aegis Capital Corp. is the placement agent; company is restricted from further share issuances for 90 days after the Release Date
Presurance Holdings reported second-quarter 2026 net income of $2.5 million, up from $2.1 million a year earlier, while earnings per share fell to $0.68 from $1.17 as the weighted share count rose to 3,746,114 from 1,746,125. Gross written premiums fell 38.0% to $13.1 million, and management attributed the decline to underwriting discipline and the runoff of commercial lines.
Q2 2026 net income was $2.5 million ($0.68 per share) versus $2.1 million ($1.17 per share) in Q2 2025
Combined ratio improved to 69.5% from 121.1%; six-month combined ratio was 86.4% versus 131.2%
Gross written premiums fell 38.0% to $13.1 million; net earned premiums fell 28.8% to $6.8 million
Book value was $7.41 per share at June 30, 2026, compared with $16.15 a year earlier
Suncrete reported second-quarter 2026 revenue of $97.2 million, up 146% from $39.5 million a year earlier, driven by recent acquisitions. The net loss widened to $37.1 million from $325,000, mainly due to a $26.9 million non-cash charge tied to the business combination and $12.2 million in acquisition-related costs. The company kept its 2026 guidance, which calls for revenue of $420 million to $480 million and a net loss of $(31) million to $(7) million.
Revenue was $97.2 million versus $39.5 million a year earlier; total yards delivered rose 123%.
Net loss was $37.1 million versus $325,000, including a $26.9 million non-cash charge and $12.2 million in acquisition-related costs.
Adjusted EBITDA was $13.5 million versus $7.0 million; Supplemental Adjusted EBITDA was $14.6 million versus $7.7 million.
2026 guidance was maintained: revenue of $420 million to $480 million and Adjusted EBITDA of $68 million to $93 million.
Galectin Therapeutics reported its June 30, 2026 quarterly results, with a net loss applicable to common stockholders of $9.2 million, or $0.14 per share, up from $7.6 million, or $0.12 per share, a year earlier. The increase was mainly due to a $3.2 million charge for the change in fair value of derivative liabilities, and the company also reported that a $105.8 million debt conversion into common stock strengthened its balance sheet and that it reached FDA alignment on its planned Phase 3 trial.
Q2 2026 net loss applicable to common stockholders was $9.2 million, or $0.14 per share, versus $7.6 million, or $0.12 per share, in Q2 2025
Chairman Richard Uihlein's conversion of about $105.8 million in debt and accrued interest into 34,376,167 common shares took effect July 31, 2026
Cash and cash equivalents were $13.2 million at June 30, 2026, with $10 million remaining under the chairman's line of credit; the company expects cash to fund planned operations through June 2027
The company expects to submit the registrational Phase 3 protocol for belapectin in the third quarter of 2026
LanzaTech reported second-quarter 2026 net income of $184.3 million, compared with a net loss of $32.5 million a year earlier, mainly because of a $208.1 million non-cash unrealized gain on its SGLT investment. Revenue slipped to $9.0 million from $9.1 million, while operating expenses fell to $11.7 million from $35.1 million and Adjusted EBITDA loss narrowed to $7.6 million from $29.7 million. The company also reintroduced 2026 guidance, with full-year revenue of $50 million to $55 million and full-year Adjusted EBITDA of $(22) million to $(26) million.
Net income of $184.3 million versus a net loss of $32.5 million, driven by the $208.1 million non-cash gain on the SGLT investment
Revenue of $9.0 million, down from $9.1 million; operating expenses of $11.7 million, down from $35.1 million
Adjusted EBITDA loss of $7.6 million, compared with $29.7 million in the second quarter of 2025
Reintroduced guidance: third-quarter 2026 revenue of $8 million to $11 million; full-year 2026 revenue of $50 million to $55 million and Adjusted EBITDA of $(22) million to $(26) million
Digi Power X reported revenue of approximately $6.6 million and a net loss of approximately $14.4 million for the quarter ended June 30, 2026, including its first AI compute revenue of approximately $1.1 million. The company also set a 2027 target of $250 million to $300 million in annualized revenue run-rate by Q3 2027, which depends on customer contracts, deployments and financing. For shareholders, the quarter shows early AI revenue alongside a large loss, and the outlook remains conditional on execution and financing.
Q2 2026 revenue of approximately $6.6 million and net loss of approximately $14.4 million
Adjusted EBITDA of approximately $3.3 million, compared with approximately $0.1 million in the prior-year period
2027 outlook targets an annualized revenue run-rate of $250 million to $300 million by Q3 2027
Cash of $142.4 million as of June 30, 2026; Goldman Sachs engaged to help syndicate Alabama data center debt financing
At an August 12, 2026 extraordinary meeting, shareholders approved amendments that allow RF Acquisition Corp II to extend its deadline to complete a business combination from August 15, 2026 up to six one-month extensions, to February 15, 2027. Each extension requires a $75,000 deposit into the trust account, recorded as a non-interest bearing, unsecured promissory note payable upon a business combination. Holders of 833,157 shares redeemed for about $9,277,866.57, leaving about $44,522,115.92 in the trust account.
Shareholders approved the Articles Amendment and Trust Agreement Amendment on August 12, 2026, with 6,767,656 votes for and 260,877 against each, and no abstentions.
Up to six one-month extensions from August 15, 2026, to February 15, 2027, with a $75,000 trust deposit for each monthly extension.
Holders of 833,157 shares redeemed for about $9,277,866.57 (about $11.13 per share); about $44,522,115.92 remains in the trust account.
The company gave up its right to withdraw up to $100,000 of trust interest to pay liquidation and dissolution expenses; 3,998,108 ordinary shares remain outstanding after the redemption.
EDAP TMS agreed on August 11, 2026 to sell 8,425,000 American Depositary Shares at $4.75 each in an underwritten public offering, with closing expected August 14, 2026. Expected net proceeds of about $37.1 million will fund operating costs, capital expenditures and general corporate purposes, including working capital. The sale adds new shares that will dilute existing holders, and the underwriters hold a 30-day option to buy up to 1,263,750 more ADSs.
8,425,000 ADSs offered at $4.75 per ADS before underwriting discounts and commissions
Expected net proceeds of about $37.1 million, before any sale under the underwriters' option
Underwriters hold a 30-day option to buy up to 1,263,750 additional ADSs
Executive officers and directors agreed to a 90-day lock-up, subject to exceptions and waiver by the representatives
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.